Paper42395877
Engineered extracellular vesicles for ischemic heart diseases: modification methods, targeted delivery strategies, and multi-modal therapies - A systematic review.
Su S and 4 others. Front Cardiovasc Med, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Engineered extracellular vesicles for ischemic heart diseases: modification methods, targeted delivery strategies, and multi-modal therapies - A systematic review. Papers, record 42395877. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42395877
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Engineered extracellular vesicles for ischemic heart diseases: modification methods, targeted delivery strategies, and multi-modal therapies - A systematic review.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References106
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40453695 | Human induced pluripotent stem cell derived nanovesicles for cardiomyocyte protection and proliferation. | Bioact Mater | 2025 | https://conductscience.org/library/papers/40453695 | PubMed |
| 2 | 32076644 | Targeted anti-IL-1β platelet microparticles for cardiac detoxing and repair. | Sci Adv | 2020 | https://conductscience.org/library/papers/32076644 | PubMed |
| 3 | 40514650 | Nanoscale engineered exosomes for dual delivery of Sirtuin3 and insulin to ignite mitochondrial recovery in myocardial ischemia-reperfusion. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/40514650 | PubMed |
| 4 | 38001231 | Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction. | Nat Rev Cardiol | 2024 | https://conductscience.org/library/papers/38001231 | PubMed |
| 5 | 29556361 | Targeting regenerative exosomes to myocardial infarction using cardiac homing peptide. | Theranostics | 2018 | https://conductscience.org/library/papers/29556361 | PubMed |
| 6 | 40064701 | Platelet Membrane and miR-181a-5p Doubly Optimized Nanovesicles Enhance Cardiac Repair Post-Myocardial Infarction through Macrophage Polarization. | ACS Appl Mater Interfaces | 2025 | https://conductscience.org/library/papers/40064701 | PubMed |
| 7 | 17003929 | Potential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix. | Thromb Haemost | 2006 | https://conductscience.org/library/papers/17003929 | PubMed |
| 8 | 41152363 | Targeting SYK with miR-512-3p provides therapeutic potential in myocardial fibrosis. | Sci Rep | 2025 | https://conductscience.org/library/papers/41152363 | PubMed |
| 9 | 37439246 | Exosomes: current knowledge and future perspectives. | Tissue Barriers | 2024 | https://conductscience.org/library/papers/37439246 | PubMed |
| 10 | 23584393 | Extracellular vesicles: biology and emerging therapeutic opportunities. | Nat Rev Drug Discov | 2013 | https://conductscience.org/library/papers/23584393 | PubMed |
| 11 | 40886088 | Participation of Women in Cardiovascular Trials From 2017 to 2023: A Systematic Review. | JAMA Netw Open | 2025 | https://conductscience.org/library/papers/40886088 | PubMed |
| 12 | 32145393 | Pre-culture of mesenchymal stem cells within RGD-modified hyaluronic acid hydrogel improves their resilience to ischaemic conditions. | Acta Biomater | 2020 | https://conductscience.org/library/papers/32145393 | PubMed |
| 13 | 21501867 | Cell penetrating peptide conjugated bioreducible polymer for siRNA delivery. | Biomaterials | 2011 | https://conductscience.org/library/papers/21501867 | PubMed |
| 14 | 41919239 | Mechanisms and emerging research trends of angiogenesis promotion by small extracellular vesicles from different cellular sources in alleviating myocardial infarction injury. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41919239 | PubMed |
| 15 | 38417558 | Locally delivered hydrogels with controlled release of nanoscale exosomes promote cardiac repair after myocardial infarction. | J Control Release | 2024 | https://conductscience.org/library/papers/38417558 | PubMed |
| 16 | 33621039 | A Novel Peptide-Equipped Exosomes Platform for Delivery of Antisense Oligonucleotides. | ACS Appl Mater Interfaces | 2021 | https://conductscience.org/library/papers/33621039 | PubMed |
| 17 | 32278100 | MiR-101a loaded extracellular nanovesicles as bioactive carriers for cardiac repair. | Nanomedicine | 2020 | https://conductscience.org/library/papers/32278100 | PubMed |
| 18 | 36325775 | [MicroRNA-204 Carried by Exosomes of Human Umbilical Cord-derived Mesenchymal Stem Cells Regulates the Polarization of Macrophages in a Mouse Model of Myocardial Ischemia-reperfusion Injury]. | Zhongguo Yi Xue Ke Xue Yuan Xue Bao | 2022 | https://conductscience.org/library/papers/36325775 | PubMed |
| 19 | 41674372 | Fusogenic Hybrid Gelled Nanovesicles Combining Mesenchymal Stromal Cell Cargo with Cholesterol-Modified Macrophage Membranes for Targeted Myocardial Infarction Therapy. | ACS Nano | 2026 | https://conductscience.org/library/papers/41674372 | PubMed |
| 20 | 33664870 | Engineering extracellular vesicles with platelet membranes fusion enhanced targeted therapeutic angiogenesis in a mouse model of myocardial ischemia reperfusion. | Theranostics | 2021 | https://conductscience.org/library/papers/33664870 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42395877
GET https://conductscience.org/api/papers/v1/42395877/references?page=2